N. Barnes (London, United Kingdom), E. Derom (Gent, Belgium)
The effect of ketoconazole on the pharmacokinetics (PK) and pharmacodynamics (PD) of inhaled fluticasone furoate (FF) and vilanterol (VI) administered in combination in healthy subjects
R. Kempsford, A. Allen, J. Bal, D. Rubin, L. Tombs (Stevenage, Uxbridge, Slough, United Kingdom; Research Triangle Park, United States Of America)
|  |
Vilanterol, a novel inhaled long-acting β2 adrenoceptor agonist (LABA), demonstrates extensive first pass clearance to metabolites with negligible pharmacological activity in man
A. Harrell, S. Siederer, J. Bal, R. Kempsford (Ware, Stevenage, Stockley Park, United Kingdom)
| |
Safety, pharmacokinetics (PK) and pharmacodynamics (PD) of single doses of GSK573719 inhalation powder, a new long-acting muscarinic antagonist (LAMA), in patients with COPD
R. Mehta, A. Newlands, D. Kelleher, A. Preece, A. Cahn, G. Crater (Research Triangle Park, United States Of America; Uxbridge, Stevenage, United Kingdom)
| |
The pharmacodynamics of GSK961081 in patients with COPD
V. Norris, C. Q. Zhu, C. Ambery (Stevenage, Uxbridge, United Kingdom)
| |
The safety, tolerability, pharmacodynamics and pharmacokinetics of inhaled fluticasone furoate (FF) and vilanterol (VI) are unaffected by administration in combination
R. Kempsford, A. Allen, P. Bareille, H. Bishop, M. Hamilton, A. Cheesbrough (Stevenage, Uxbridge, Ware, United Kingdom)
| |
Aspirin inhalation treatment for COPD patients: Preliminary studies on PK and inflammatory biomarkers
A. Soleti, G. Zuccari, C. Omini (Torino, Paullo, Italy)
| |
Pharmacokinetic bioequivalence of inhaled CHF 1535 50/6 vs. the free combination of beclomethasone and formoterol in asthmatic children
B. L. K. Chawes, A. Piccinno, E. Kreiner-Møller, N. L. Skytt, N. Samandari, F. Sergio, G. Ciurlia, D. Acerbi, H. Bisgaard (Gentofte, Denmark; Parma, Italy)
| |
Contamination and carry-over in clinical pharmacokinetic trials with aerosolized budesonide
D. Kappeler, D. Zanker, B. Daumann, O. Eickelberg, T. Meyer (Gauting, Munich, Germany)
| |
Fluticasone/salmeterol combined in the new Forspiro® inhaler is as effective and safe as Seretide® Accuhaler® in adult and pediatric asthmatics
P. Kuna, U. Thyroff-Friesinger, I. Gath (Lodz, Poland; Holzkirchen, Germany)
| |
Effect of systemic and extra-fine particle inhaled corticosteroids on corrected alveolar nitric oxide (CANO) in COPD
P. Williamson, P. Short, B. Lipworth (Dundee, United Kingdom)
| |
Lung deposition of the extrafine dry powder fixed combination beclomethasone dipropionate plus formoterol fumarate via the NEXT DPI® in healthy subjects, asthmatic and COPD patients
F. Mariotti, F. Sergio, D. Acerbi, T. Meyer, C. Herpich (Parma, Italy; Gauting, Germany)
| |
A novel NEXT DPI® dry powder inhaler and its use in asthmatic and COPD population
F. Sergio, A. Chetta, G. Pisi, M. Aiello, D. Olivieri (Parma, Italy)
| |
Efficiency of ipratropium bromide and salbutamol deposition in the lung delivered via a soft-spray inhaler or chlorofluorocarbon metered-dose inhaler
M. Ghafouri (Ridgefield, United States Of America)
|  |
Maintenance of lung function and asthma control with extrafine beclomethasone/formoterol
N. Barnes, J. A. Van Noord, C. Brindicci, L. Lindemann, G. Varoli, M. Perpina, D. Guastalla, D. Casula, P. Chanez (London, United Kingdom; Heerlen, Netherlands; Parma, Italy; Gelsenkirchen, Germany; Valencia, Spain; Marseille, France)
| |
Phase II study of once-daily GSK573719 inhalation powder, a new long-acting muscarinic antagonist, in patients with chronic obstructive pulmonary disease (COPD)
D. Kelleher, A. Preece, R. Mehta, A. Donald, K. Hardes, A. Cahn, G. Crater (Research Triangle Park, United States Of America; Uxbridge, Stevenage, United Kingdom)
| |
Optimization of inhalation treatment – Evaluation of influence of PNEUMOlogic® and Optimiser® spacers on aerosol particle distribution from pMDI-EB
Z. Podolec, J. Siekaniec (Cracow, Poland)
| |
In vitro comparison of aerosol characteristics of HFA ipratropium bromide pressurized metered dose inhaler (pMDI) formulation from three valved holding chambers (VHCs)
K. Nikander, L. Slator, D. von Hollen, R. Hatley (Parsippany, United States Of America; Chichester, United Kingdom)
| |
Airway humidity during oxygen therapy: Impact of humidification and applicator design
M. Wenzel, D. Dellweg, E. Höhn, O. Bourgund, P. Haidl (Schmallenberg, Germany)
| |
Objective measurement of inhalation profiles in patients using metered dose inhalers (MDIs)
W. Azouz, P. Chetcuti, H. Hosker, D. Saralaya, H. Chrystyn (Huddersfield, Leeds, Steeton, Bradford, United Kingdom)
| |
In-vitro nebulised dose emission characteristics of a tobramycin solution (75mg/ml) using an I-Neb (I-NEB) and a pari LC+ driven by a TurboBoy compressor (PARI) nebuliser
M. Y. Khan, N. Powles, M. Stirling, H. Chrystyn (Huddersfield, United Kingdom)
| |